visit us at booth #13

VISIT US AT BOOTH #13
TH
TH
JOIN US ON 17 MAY – 10:00 / ROOM 5 TO WATCH OUR 10 ANNIVERSARY FILMS
DNDi SATELITE SYMPOSIUMS
th
•
•
•
•
•
th
May 13 Monday [3:45 pm – 5:30 pm / Room 3 – Francisco Brennand (1-4)]
May 15 Wednesday [2:00 pm – 4:30 pm / Room 1 – Amália Rodrigues]
Asymptomatic Infections
Therapeutics: New treatments for Leishmaniasis
Evidence suggests that large numbers of individuals in endemic areas are infected with L. donovani
without developing any signs or symptoms of actual VL disease. The reported ratio of asymptomatic
infections to VL clinical cases varies widely, for example, from 4:1 in Kenya to 50:1 in Spain. This
variation is presumed to reflect differences in parasite virulence and host population characteristics,
but may also depend on study design and tests used to define asymptomatic infection. Determining
whether asymptomatic carriers are infective to sand flies is crucial to be able to provide appropriate
control measures: it is essential to understand the factors associated with asymptomatic infections to
design and implement optimal prevention and control strategies, as asymptomatically infected
individuals can harbor latent parasite and eventually act as reservoirs for new infections, or become
ill if immunosuppression occurs. Identifying the biomarkers that properly define the concept of
“asymptomatic carrier” and the role these may play in disease transmission is urgently needed.
Whether they should be preventively treated or not is a crucial landmark for elimination
programmes.
Co-chairs: Hannah Akufo, SIDA and Jorge Alvar, DNDi
Presentations:
Lessons learned: from dogs to immunosuppression - Javier Moreno, ISCIII
Asymptomatic infections versus self-cure - Selma Jerônimo, UFRN
The Indian experience, Epco Hasker, ITM
The African experience, Abu Said, IED
Modelling asymptomatic infections in the transmission cycle, Caryn Bern, UCSF
The last decade has seen improvements in treatment, diagnosis, and prevention of leishmaniasis in
South Asia, notably through the development of liposomal Amphotericin B, paromomycin and
miltefosine. Through a combination of active case detection, early treatment, vector control and
social mobilization, the WHO expects to reach its aim of eliminating anthroponotic visceral
leishmaniasis from the Indian sub-continent by 2020.1 More work however is needed to consolidate
the progress achieved in South Asia and extend it to other parts of the world, in particular to East
Africa and Latin America. Indeed, response to treatment has been shown to vary between and within
regions, with higher doses of drugs required in East Africa and Latin America than in South Asia and
evidence of geographical variations within East Africa. While the progress achieved has led to a
clearer concept as to how to treat patients across different continents, existing treatments are not
perfect: potential of resistance development, low tolerability, long treatment duration and difficulty
in administration, as well as high cost are major drawbacks. New treatments that address these
issues and cater for geographical variations and local realities are essential, notably in East Africa.
•
•
•
•
Co-chairs: Simon Croft, LSTMH and Fabiana Alves, DNDi
Presentations:
Combination treatments in East Africa – Ahmed Musa, IEND/LEAP Platform
VL Brazil trial, current status and interim safety analysis – Gustavo Romero, UNB
New drugs for leishmaniasis: from screening to new candidates for clinical development – Charles
Mowbray, DNDi
Screening of oral drugs/compounds against CL – Ingrid Mueller, Imperial College, UK
Challenges in Drug Discovery and Translation
Co-chairs: Ana Rabelo, Oswaldo Cruz Foundation and Simon Croft, LSTMH
Presentations:
•
Animal Models in the Evaluation and Optimisation of New Dugs for Visceral and Cutaneous
Leishmaniasis – Simon Croft, LSTMH
•
New Drugs for Leishmaniasis: Discovery Model – Dr Charles Mowbray, DNDi
•
An Evaluation of WHO Standard Leishmania Strains, Jeffrey Shaw, USP
1
Sustaining the drive to overcome the global impact of neglected tropical diseases: second WHO report on neglected
tropical diseases World Health Organization, 2013
Drugs for Neglected Diseases initiative, Latin America ■ Rua Santa Heloísa, Jardim Botânico, Rio de Janeiro, RJ, Brazil – CEP 22460-080
Tel: +55 (21) 2215 2941 ■ Email: [email protected] ■ Web: www.dndi.org.br
DNDi RECOMMENDS!
th
May 13 Monday
1.BANARAS HINDU UNIVERSITY, VARANASI, ÍNDIA; 2.INSTITUTE OF TROPICAL MEDICINE, ANTWERP,
BÉLGICA.
2:00 pm – 3:30 pm / Room 4 – Francisco Brennand (5 & 6)
•
Post-Kala Azar Dermal leishmaniasis (PKDL): Clinical aspects and role in
transmission - Introduction of a PKDL Consortium
•
Co-chairs: Ed Zijlstra, DNDi and Philippe Desjeux, Formerly PATH/OWH
Presentations:
•
THE POST KALA-AZAR DERMAL LEISHMANIASIS (PKDL) CONSORTIUM
EDUARD EVERT ZIJLSTRA1; PHILIPPE DESJEUX2
1.DRUGS FOR NEGLECTED DISEASES INITIATIVE, GENEVA, SUÍÇA; 2.FORMERLY: PATH/OWH, DIVONNE,
FRANÇA.
•
•
THE ROLE OF PKDL IN TRANSMISSION OF LEISHMANIA DONOVANI BY OLD WORLD
PHLEBOTOMINE SAND FLIES: REVIEW OF EVIDENCE AND RESEARCH PRIORITIES
DIA-ELDIN AHMED ELNAIEM UNIV.OF MARYLAND EASTERN SHORE, PRINCESS ANNE, EUA.
AN OBSERVATIONAL STUDY IN BANGLADESH TO DETERMINE THE INCIDENCE OF POSTKALA-AZAR DERMAL LEISHMANIASIS AMONG INDIVIDUALS TREATED FOR VISCERAL
LESIHMANIASIS WITH DIFFERENT TREATMENT REGIMENS.
RASHIDUL HAQUE1; DINESH MONDAL1; AMRESH KUMAR2; SYED MISBAH HASSAN2; SONALI
KOCHHAR2; PRITU DHALARIA2; RAJ SHANKAR GHOSH2
1.RAJINDRA MEMORIAL RESEARCH INSTITUTE, PATNA, ÍNDIA; 2.MEDECINS SANS FRONTIERES, NEW
DELHI, ÍNDIA.
•
POST KALA-AZAR DERMAL LEISHMANIASIS IN INDIA – PITFALLS IN DIAGNOSIS
POONAM SALOTRA; NATIONAL INSTITUTE OF PATHOLOGY (ICMR), NEW DELHI, ÍNDIA.
•
MANAGEMENT OF PKDL UNDER FIELD CONDITIONS IN BANGLADESH: OUTCOMES OF
SHORT-COURSE LIPOSOMAL AMPHOTERICIN B REGIMEN
MARGRIET DEN BOER; SUZANNE VELDHUIS; ULRIKA MARKING; ELSHAFIE MOHAMED
AHMED; ASISH KUMAR D; KOERT RITMEIJER
MÉDECINS SANS FRONTIÈRES, AMSTERDAM, HOLANDA.
•
CLINICAL DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS OF POST-KALA-AZAR DERMAL
LEISHMANIASIS (PKDL)
EDUARD EVERT ZIJLSTRA1; V RAMESH2
1.ROTTERDAM CENTRE FOR TROPICAL MEDICINE, ROTTERDAM, HOLANDA; 2.SAFDARJUNG HOSPITAL
AND VARDHMAN MAHAVIR MEDICAL COLLEGE, NEW DELHI, ÍNDIA.
•
•
SYSTEMATIC REVIEW INTO DIAGNOSTICS FOR PKDL
EMILY ADAMS1; INGE VERSTEEG2; MARISKA LEEFLANG3
1.LIVERPOOL SCHOOL OF TROPICAL MEDICINE, LIVERPOOL, REINO UNIDO; 2.ROYAL TROPICAL INSTITUTE,
AMSTERDAM, HOLANDA; 3.AMC, AMSTERDAM, HOLANDA.
•
POINT-OF-CARE DIAGNOSIS OF POST-KALA-AZAR-DERMAL LEISHMANIASIS (PKDL) FROM
URINE SAMPLES BY USING RK-39 STRIP TEST.
DHARMENDRA SINGH; KRISHNA PANDEY; VIDHYA NAND DAS; NEENA VERMA; SUSHMITA
DAS; ROSHAN KAMAL TOPNO; PRADEEP DAS
RAJENDRA MEMORIAL RESEARCH INSTITUTE OF MEDICAL SCIENCES, AGAMKUAN, PATNA, ÍNDIA.
•
CARE-SEEKING OF POST-KALA-AZAR DERMAL LEISHMANIASIS PATIENTS IN TWO KALAAZAR HIGH ENDEMIC SUB-DISTRICTS OF MYMENSINGH, BANGLADESH
KAZI MIZANUR RAHMAN1; DINESH MONDAL2; STEPHEN P. LUBY3; COLIN D BUTLER4
1.AUSTRALIAN NATIONAL UNIVERSITY, CANBERRA, AUSTRÁLIA; 2.INTERNATIONAL CENTRE FOR
DIARRHOEAL DISEASE RESEARCH, BANGLADESH, DHAKA, BANGLADESH; 3.STANFORD UNIVERSITY,
STANFORD, ESTADOS UNIDOS; 4.UNIVERSITY OF CANBERRA, BRUCE, AUSTRÁLIA.
Post-Kala Azar Dermal leishmaniasis (PKDL) Symposium #2
POST-KALA-AZAR DERMAL LEISHMANIASIS (PKDL) IN VISCERAL LEISHMANIASIS ENDEMIC
COMMUNITIES IN BIHAR, INDIA
RUDRA PRATAP SINGH1; ALBERT PICADO2; SHAHNAWAZ ALAM1; EPCO HASKER2; SHRI
PRAKASH SINGH1; BART OSTYN2; SHYAM SUNDAR1; MARLEEN BOELAERT2
THE LEISHMANIA INFANTUM MITOCHONDRIAL TRYPAREDOXIN PEROXIDASE – A
TEMPERATURE-REGULATED CHAPERONE ESSENTIAL TO PARASITE INFECTIVITY?
ANA M TOMAS1; FILIPA TEIXEIRA1; HELENA CASTRO1; DANIEL SOUTHWORTH2; URSULA
JAKOB3
1.INSTITUTE FOR MOLECULAR AND CELL BIOLOGY, PORTO, PORTUGAL; 2.DEPARTMENT OF BIOLOGICAL
CHEMISTRY, UNIVERSITY OF MICHIGAN MEDICAL SCHOO, ANN ARBOR, ESTADOS UNIDOS;
3.DEPARTMENT OF MOLECULAR, CELLULAR, AND DEVELOPMENTAL BIOLOGY, UNIVERSITY OF MICHIGAN,
ANN ARBOR, ESTADOS UNIDOS.
3:45 pm – 6:00 pm / Room 4 – Francisco Brennand (5 & 6)
•
TREATMENT OF POST KALA-AZAR DERMAL LEISHMANIASIS IN INDIAN SUBCONTINENT- A
REVIEW
ANUP SINGH; SHYAM SUNDAR
DEPARTMENT OF MEDICINE,INSTITUTE OF MEDICAL SCIENCES,BANARAS HINDU UNIVERSITY, VARANASI,
ÍNDIA.
1.ICDDR,B, DHAKA, BANGLADESH; 2.PATH-OWH, DELHI, ÍNDIA.
•
EPIDEMIOLOGICAL STUDY TO ASSESS THE PREVALENCE OF PKDL IN ENDEMIC AREAS OF
BIHAR.
VIDYA NAND RABIDAS; KRISHANA PANDEY; ROSHAN KAMAL TOPNO; PRADEEP DAS
RMRIMS, PATNA, ÍNDIA.
SAFETY AND EFFICACY OF LIPOSOMAL AMPHOTERICIN B (L-AMB) FOR TREATMENT OF
POST KALA-AZAR DERMAL LEISHMANIASIS (PKDL) IN BIHAR, INDIA
PRABHAT KUMAR SINHA1; SAKIB BURZA2; RAMAN MAHAJAN2; KRISHNA PANDEY1; VIDYA
DAS1; NAWIN KUMAR1; NINA VERMA1; CHANDRA LAL1; MARIA ANGELES LIMA2; PRADEEP
DAS1
•
EFFICACY AND SAFETY OF PAROMOMYCIN IN TREATMENT OF POST KALA AZAR DERMAL
LEISHMANIASIS (PKDL)
JAYA TAPADAR; SHYAM SUNDAR; ANUP SINGH; ANURAG TIWARI; SAURABH SHUKLA;
Drugs for Neglected Diseases initiative, Latin America ■ Rua Santa Heloísa, Jardim Botânico, Rio de Janeiro, RJ, Brazil – CEP 22460-080
Tel: +55 (21) 2215 2941 ■ Email: [email protected] ■ Web: www.dndi.org.br
MADHUKAR RAI
DEPARTMENT OF MEDICINE,INSTITUTE OF MEDICAL SCIENCES, BANARAS HINDU UNIVERSITY, VARANASI, ÍNDIA.
th
May 15 Wednesday
SCIENCES - FEDERAL UNIVERSITY OF MINAS GERAIS, BELO HORIZONTE, MG, BRASIL; 3.HOSPITAL
EDUARDO DE MENEZES, BELO HORIZONTE, MG, BRASIL; 4.LABORATORY OF CLINICAL RESEARCH –
CENTRO DE PESQUISAS RENÉ RACHOU - FUNDAÇÃO OSWALDO CRUZ, FIOCRUZ, BELO HORIZONTE, MG,
BRASIL.
9:45 am – 10:30 am / Room 1 – Amália Rodrigues
Drugs Everywhere!
•
THE AVAILABILITY OF MEDICINES FOR THE TREATMENT OF LEISHMANIASIS
ANTHONY BRYCESON
•
ROTTERDAM CENTRE FOR TROPICAL MEDICINE, ROTTERDAM, HOLANDA.
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE, LONDON, REINO UNIDO.
•
TREATMENT ACCESS CHALLENGES IN LEISHMANIASIS; RECOMMENDATIONS
MARGRIET LEONTINE DEN BOER1; DANIEL ARGAW1; IVAN VELEZ2; JORGE ALVAR3
•
1.WHO, GENEVA, SUÍÇA; 2.UNIVERSITY OF ANTIOQUIA, MEDELLIN, COLÔMBIA; 3.DNDI, GENEVA, SUÍÇA.
•
ACCESS TO MEDICINES FOR VISCERAL LEISHMANIASIS: WHERE DO WE STAND ON
SOURCES, PRICES, QUALITY AND PRODUCTION SCALE-UP? THE EXAMPLE OF AMBISOME®
CAROLE ZEN-RUFFINEN1; SARA GASPANI2; MARGRIET DEN BOER3; JULIEN POTET2; BARBARA
MILANI
•
1.MEDECINS SANS FRONTIÈRES' INTERNATIONAL OFFICE, GENEVA, SUÍÇA; 2.MEDECINS SANS
FRONTIÈRES' ACCESS CAMPAIGN, GENEVA, SUÍÇA; 3.MEDECINS SANS FRONTIÈRES / ARTSEN ZONDER
GRENZEN, AMSTERDAM, HOLANDA.
•
•
EFFICACY OF ANTI-LEISHMANIA THERAPY IN VISCERAL LEISHMANIASIS AMONG HIV
INFECTED PATIENTS: A SYSTEMATIC REVIEW WITH INDIRECT COMPARISON.
GLÁUCIA FERNANDES COTA1; MARCOS ROBERTO DE SOUSA2; TATIANI OLIVEIRA
FEREGUETTI3; ANA LUCIA TELLES RABELLO4
1.LABORATORY OF CLINICAL RESEARCH – CENTRO DE PESQUISA RENE RACHOU; HOSPITAL EDUARDO DE
MENEZES-FHEMIG, BELO HORIZONTE, MG, BRASIL; 2.POST-GRADUATE PROGRAM IN ADULT HEALTH
OLD AND NEW TREATMENTS OF HIV/VL CO-INFECTION.
KOERT RITMEIJER
MÉDECINS SANS FRONTIÈRES, AMSTERDAM, HOLANDA.
VL-HIV CO-INFECTION IN SAO PAULO STATE, BRAZIL
IGOR THIAGO QUEIROZ1; JOSE ANGELO LINDOSO2
1.DEPTO DE DOENÇAS INFECCIOSAS E PARASITÁRIAS DA FMUSP, SAO PAULO, SP, BRASIL; 2.LABORATÓRIO
DE SOROEPIDEMIOLOGIA - IMT-SP, SAO PAULO, SP, BRASIL.
COMBINATION THERAPY FOR VISCERAL LEISHMANIASIS IN HIV-COINFECTED INDIVIDUALS:
ROUND TABLE: CO-INFECTION VISCERAL LEISHMANIASIS AND HIV: OLD AND NEW
APPROACHES
JOHAN VAN GRIENSVEN
INSTITUTE OF TROPICAL MEDICINE, ANTWERP, BÉLGICA.
11:15 am – 13:00 pm / Room 4 – Francisco Brennand (5 & 6)
Clinical Leishmaniasis – HIV Co-infection
PKDL AND PKDL-LIKE LESIONS IN HIV CO-INFECTION
EDUARD EVERT ZIJLSTRA
•
VISCERAL LEISHMANIASIS AND HIV IN THE AMERICAS: CURRENT SITUATION
ANA NILCE MAIA-ELKHOURY
PAN AMERICAN HEALTH ORGANIZATION-WORLD HEALTH ORGANIZATION (PAHO/WHO), RIO DE JANEIRO,
BRAZIL, RIO DE JANEIRO, RJ, BRASIL.
•
EPIDEMIOLOGY OF HIV-LEISHMANIA CO-INFECTION
JORGE ALVAR
DRUGS FOR NEGLECTED DISEASES INITIATIVE (DNDI), GENEVA, SWITZERLAND.
Drugs for Neglected Diseases initiative, Latin America ■ Rua Santa Heloísa, Jardim Botânico, Rio de Janeiro, RJ, Brazil – CEP 22460-080
Tel: +55 (21) 2215 2941 ■ Email: [email protected] ■ Web: www.dndi.org.br
th
May 16 Thursday
9:00 am – 11:00 am / Room 1 – Amália Rodrigues
Drug Development
•
UTILITY OF THE EXPERIMENTAL CUTANEOUS LEISHMANIASIS IN HAMSTERS INFECTED IN
THE DORSAL SKIN FOR IN VIVO SCREENING OF ANTILEISHMANIAL ACTIVITY.
SARA MARIA ROBLEDO1; JUAN ALEJANDRO DAZA1; ADRIANA MARIA RESTREPO1; DIANA
1
1
1
1
LORENA MUÑOZ ; JAVIER DARIO MURILLO ; ANDERSON LOPEZ ; MATTEO DUQUE ; CAROL
VANESA MESA1; YULIETH ALEXANDRA UPEGUI1; LINA MARIA CARRILLO2; IVAN DARIO VELEZ1
1.UNIVERSIDAD DE ANTIOQUIA, MEDELLIN, COLÔMBIA; 2.GERMAN CANCER RESEARCH CENTER (DKFZ),
HEIDERBERG, ALEMANHA.
•
DNDI, GENEVA, SUÍÇA.
1.PECET, UNIVERSITY OF ANTIOQUIA, MEDELLIN, COLÔMBIA; 2.PECET, AGRARIAN SCIENCES UNIVERSITY
OF ANTIOQUIA, MEDELLIN, COLÔMBIA.
•
MEMBRANE ACTIVE PEPTIDES IN THE CHEMOTHERAPY OF LEISHMANIA : FROM PIERCING
DEVICES TO DRUG SMUGGLERS.
LUIS RIVAS
14:00 pm – 16:30 pm / Room 1 – Amália Rodrigues
Drug Development #2
CENTRO DE INVESTIGACIONES BIOLÓGICAS (CSIC), MADRID, ESPANHA.
•
NOVEL TREATMENT FOR NEGLECTED TROPICAL DISEASES
NIR QVIT1; DANILO CICCONE MIGUEL2; VIVIAN BONANO2; DEBORAH SCHECHTMAN2; SILVIA
ULIANA2; DARIA MOCHLY-ROSEN1
•
1.STANFORD, PALO ALTO, ESTADOS UNIDOS; 2.UNIVERSITY OF SAO PAULO, SAO PAULO, SP, BRASIL.
•
MOLECULAR AND BIOCHEMICAL CHARACTERIZATION OF THE CHOLINE/ETHANOLAMINE
KINASE OF LEISHMANIA SPECIES
SERGIO ANDRES PULIDO1; MARIA FERNANDA FLOREZ1; JON, A FRIESEN2; JUAN FERNANDO
ALZATE1; DAVID L CEDEÑO2; MONIKA A MAKURATH2; MARJORIE A JONES2; IVAN DARIO
VELEZ3; SARA MARIA ROBLEDO1
1.PECET, UNIVERSITY OF ANTIOQUIA, MEDELLIN, COLÔMBIA; 2.ILLINOIS STATE UNIVERSITY, NORMAL,
ESTADOS UNIDOS; 3.UNIVERSITY OF ANTIOQUIA, MEDELLIN, COLÔMBIA.
•
IDENTIFICATION OF NOVEL SCAFFOLDS WITH ANTI-LEISHMANIAL ACTIVITY USING A
PHYSIOLOGICALLY RELEVANT PHENOTYPIC SCREENING PIPELINE
1
2
2
3
ERIC PRINA ; NATHALIE AULNER ; ANNE DANCKAERT ; OLIVIER HELYNCK ; ELINE ROUAULT4
2
3
HARDOIN ; SPENCER SHORTE ; HELENE MUNIER-LEHMANN ; GENEVIEVE MILON4; GERALD
SPÄTH1
1.INSTITUT PASTEUR, CNRS-URA2581, UNITÉ DE PARASITOLOGIE MOLÉCULAIRE ET SIGNALISATION,
PARIS, FRANÇA; 2.INSTITUT PASTEUR, IMAGOPOLE, PARIS, FRANÇA; 3.INSTITUT PASTEUR, CNRS, UMR
3523,UNITÉ DE CHIMIE ET BIOCATALYSE, PARIS, FRANÇA; 4.INSTITUT PASTEUR, LABORATOIRE
D'IMMUNOPHYSIOLOGIE ET PARASITISME, PARIS, FRANÇA.
•
SCREENING AGAINST LEISHMANIA INTRACELLULAR AMASTIGOTES: COMPARISON TO A
PROMASTIGOTE SCREEN AND IDENTIFICATION OF MOLECULES TARGETING HOSTENCODED FUNCTIONS.
GERALDINE DE MUYLDER1; KENNY H ANG2; STEVEN CHEN2; MICHELLE R ARKIN2; SUMAN
RIJAL3; JEAN-CLAUDE DUJARDIN4; JUAN C ENGEL1; JAMES H MCKERROW5
DRUG REPOSITIONING PREDICTION OF POTENTIAL ANTI-LEISHMANIAL COMPOUNDS
BASED ON HOMOLOGY SEARCH.
CARLOS ENRIQUE MUSKUS1; ANDRES FLOREZ2; SARA MARIA ROBLEDO1; RODRIGO OCHOA1
ANIMAL MODELS IN THE EVALUATION AND OPTIMISATION OF NEW DRUGS FOR VISCERAL
AND CUTANEOUS LEISHMANIASIS
SIMON L. CROFT
LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE, LONDON, REINO UNIDO.
•
STRUCTURE AND IMMUNOLOCALIZATION OF NEW INOSITOL PHOSPHOCERAMIDE OF
LEISHMANIA (VIANNIA) BRAZILIENSIS
ERICA VALADARES DE CASTRO; MARCOS SERGIO DE TOLEDO; RENATO ARRUDA MORTARA;
HELIO KIYOSHI TAKAHASHI; ANITA HILDA STRAUS
UNIVERSIDADE FEDERAL DE SÃO PAULO, SÃO PAULO, SP, BRASIL.
•
HEMI-SYNTHETIC DINITROANILINES IN LIPOSOMES: COMBINED STRATEGIES FOR
IMPROVING TREATMENT OF LEISHMANIA INFANTUM INFECTION
MANUELA CARVALHEIRO1; JOANA PEREIRA1; RUI LOPES1; ALEXANDRA ESTEVES2; M.
1
3
4
1
MANUELA GASPAR ; EFFIE SCOULICA ; GABRIELA SANTOS-GOMES ; M. EUGÉNIA CRUZ
1.FACULDADE DE FARMÁCIA, LISBOA, PORTUGAL; 2.LABORATÓRIO NACIONAL DE ENERGIA E GEOLOGIA,
LISBOA, PORTUGAL; 3.SCHOOL OF MEDICINE, CRETE, GRÉCIA; 4.INSTITUTO DE HIGIENE E MEDICINA
TROPICAL, LISBOA, PORTUGAL.
•
EXPLOITING LEISHMANIA STRESS SIGNALING FOR ANTI-PARASITIC DRUG DEVELOPMENT
GERALD SPÄTH
INSTITUT PASTEUR, CNRS-URA2581, UNITE DE PARASITOLOGIE MOLECULAIRE ET SIGNALISATION, PARIS,
FRANÇA.
•
1.UCSF-CENTER FOR DISCOVERY AND INNOVATION IN PARASITIC DISEASES, SAN FRANCISCO, ESTADOS
UNIDOS; 2.UCSF-SMALL MOLECULE DISCOVERY CENTER, SAN FRANCISCO, ESTADOS UNIDOS; 3.B.P
KOIRALA INSTITUTE OF HEALTH SCIENCES, DHARAN, NEPAL; 4.INSTITUTE OF TROPICAL MEDICINE,
ANTWERP, BÉLGICA; 5.UCSF-CENTER FOR DISCOVERY AND INNOVATION I PARASITIC DISEASES, SAN
FRANCISCO, ESTADOS UNIDOS.
•
NEW DRUGS FOR LEISHMANIASIS: FROM SCREENING TO NEW CANDIDATES FOR CLINICAL
DEVELOPMENT
CHARLES ERIC MOWBRAY
TATTOOING NANOPARTICLES CONTAINING AN ANTI-LEISHMANIASIS THERAPY CAN
DELIVER THE DRUG AT THE SITE OF PARASITE REPLICATION IN MOUSE MODELS OF
CUTANEOUS LEISHMANIASIS.
MARINA TEMI SHIO1; MARILENE PAQUET2; CAROLINE MARTEL3; STEF STIENSTRA4; HERWIG
JANSEN5; MARTIN OLIVIER1; ANNIE FORTIN6
1.DEPARTMENTS OF MEDICINE AND OF MICROBIOLOGY & IMMUNOLOGY, MCGILL UNIVERSITY,
MONTREAL, CANADÁ; 2.COMPARATIVE MEDICINE AND ANIMAL RESOURCES CENTRE, MCGILL
UNIVERSITY, MONTREAL, CANADÁ; 3.DEPARTMENTS OF MEDICINE AND OF MICROBIOLOGY AND
IMMUNOLOGY, MCGILL UNIVERSITY, MONTREAL, CANADÁ; 4.MT-DERM, BERLIN, ALEMANHA; 5.DAFRA
PHARMA RESEARCH & DEVELOPMENT, TURNHOUT, BÉLGICA; 6.DEPARTMENT OF BIOCHEMISTRY, MCGILL
UNIVERSITY, MONTREAL, CANADÁ.
•
STAT4 IS CRITICAL FOR IMMUNITY BUT NOT FOR ANTILEISHMANIAL ACTIVITY OF
ANTIMONIALS IN EXPERIMENTAL VISCERAL LEISHMANIASIS
Drugs for Neglected Diseases initiative, Latin America ■ Rua Santa Heloísa, Jardim Botânico, Rio de Janeiro, RJ, Brazil – CEP 22460-080
Tel: +55 (21) 2215 2941 ■ Email: [email protected] ■ Web: www.dndi.org.br
1
1
1
1
GAURAV GUPTA ; HEIDI STEINKAMP ; SANJA VARIKUTI ; STEVE OGHUMU ; TRACEY L
PAPPENFUSS1; MARK H KAPLAN2; ABHAY R SATOSKAR1
•
1.OSU, COLUMBUS, ESTADOS UNIDOS; 2.UNIVERSITY OF INDIANA, INDIANAPOLLIS, ESTADOS UNIDOS.
•
COMPUTATIONAL MODELS OF ANTI-LEISHMANIAL IMMUNITY: NEW TOOLS FOR DRUG
AND VACCINE DEVELOPMENT
PAUL MARTIN KAYE; DANIEL MOYO; LYNETTE BEATTIE; LUCA ALBERGANTE; PAUL
ANDREWS; JON TIMMIS
WHO, GENEVA, SUÍÇA.
•
UNIVERSITY OF YORK, YORK, REINO UNIDO.
•
A SNAPSHOT OVER MORPHOLOGY AND DIVISION OF CULTURED LEISHMANIA INFANTUM
PARASITES. ARE THESE FEATURES IMPORTANT TO ACCESS THERAPEUTICS ACTIVITY OVER
THESE PARASITES?
GRAÇA ALEXANDRE-PIRES1; GUADALUPE CABRAL2; ARMANDA RODRIGUES3; DAVID SANTOSMATEUS3; TELMO NUNES4; DÁRIO LIGEIRO5; ISABEL PEREIRA DA FONSECA1; GABRIELA
SANTOS-GOMES3
TRANSLATION FROM WHO RECOMMENDATION TO IMPLEMENTATION IN NATIONAL
POLICY
SALLY JANE ELLIS1; AHMED M MUSA2; SAKIB BURZA3; EMILIE ALIROL4; NINES LIMA5;
FRANCOIS CHAPPUIS4; ASRAT HAILU6; ELTAHIR A.G KHALIL2; JOSEPH OLOBO7; MONIQUE
WASUNNA1; BHAWNA SHARMA1; MANICA BALASEGRAM
1.DNDI, GENEVA, SUÍÇA; 2.INSTITUTE OF ENDEMIC DISEASES, KHARTOUM, SUDAO; 3.MSF, DELHI, ÍNDIA;
4.HOPITAUX UNIVERSITAIRES DE GENEVE, MEDECINS SANS FRONTIERES, GENEVA, SUÍÇA; 5.MSF SPAIN,
BARCELONA, ESPANHA; 6.ADDIS ABABA UNIVERSITY, ADDIS ABABA, ETIOPIA; 7.MAKERERE UNIVERSITY,
KAMPALA, UGANDA.
•
1.1CIISA, FACULDADE DE MEDICINA VETERINÁRIA, LISBOA, PORTUGAL; 2.CEDOC FACULDADE DE CIENCIAS
MEDICAS, LISBOA, PORTUGAL; 3.UNIDADE DE ENSINO E INVESTIGACAO DE PARASITOLOGIA MEDICA,
UNIVERSIDADE NOVA DE LISBOA, LISBOA, PORTUGAL; 4.CENTRO DE MICROSCOPIA ELECTRONICA,
FACULDADE DE CIENCIAS, LISBOA, PORTUGAL; 5.CHSUL, LISBOA, PORTUGAL.
•
FROM EVIDENCE-BASED RECOMMENDATIONS TO TREATMENT ACCESS: WORLD HEALTH
ORGANIZATION (WHO) PROCESS FOR ISSUING EVIDENCE-BASED RECOMMENDATIONS
AND GUIDELINES.
DANIEL ARGAW DAGNE
SHORT ORAL TREATMENT WITH OLEYLPHOSPHOCHOLINE IMPROVES CLINICAL CANINE
LEISHMANIASIS DUE TO LEISHMANIA INFANTUM IN A NATURAL MODEL OF INFECTION.
ANNIE FORTIN1; TOM BOSSCHAERTS2; LETICIA HERNÁNDEZ3; ANA MONTOYA3; ROSA
3
3
3
3
2
GÁLVEZ ; DIANA DADO ; ROCIO CHECA ; ALBA BELLO ; HERWIG JANSEN ; GUADALUPE
3
MIRÓ
RETROSPECTIVE QUARTERLY COHORT MONITORING FOR PATIENTS WITH VISCERAL
LEISHMANIASIS IN THE INDIAN SUBCONTINENT: HOW TO ASSESS CLINICAL OUTCOMES.
BART J.A. OSTYN1; PARITOSH MALAVIYA2; EPCO HASKER1; SURENDRA URANW3; RUDRA
PRATAP SINGH2; SUMAN RIJAL3; SHYAM SUNDAR2; JEAN-CLAUDE DUJARDIN1; MARLEEN
BOELAERT1
1.INSTITUTE OF TROPICAL MEDICINE, ANTWERP, BELGIUM, ANTWERP, BÉLGICA; 2.BANARAS HINDU
UNIVERSITY, VARANASI, ÍNDIA; 3.B.P.KOIRALA INSTITUTE OF HEALTH SCIENCES, DHARAN, NEPAL.
•
VISCERAL LEISHMANIASIS CONTROL IN SOUTH AMERICA: TIME TO REINSTATE DDT?
1
2
CARLOS BRISOLA MARCONDES ; CARLOS HENRIQUE NERY COSTA
1.FEDERAL UNIVESITY OF SANTA CATARINA, FLORIANÓPOLIS, SC, BRASIL; 2.FEDERAL UNIVESITY OF PIAUÍ,
TERESINA, PI, BRASIL.
1.DEPARTMENT OF BIOCHEMISTRY, MCGILL UNIVERSITY, MONTREAL, CANADÁ; 2.DAFRA PHARMA
RESEARCH & DEVELOPMENT, TURNHOUT, BÉLGICA; 3.DEPARTAMENTO DE SANIDAD ANIMAL, FACULTAD
DE VETERINARIA, UNIVERSIDAD COMPLUTENSE DE MADRID, MADRID, ESPANHA.
•
3:00 pm – 4:30 pm / Room 3 – Francisco Brennand (1-4)
DOG CULLING AND INSECTICIDES IN BRAZIL: AN EVIDENCE BASED APPROACH.
GUSTAVO ADOLFO SIERRA ROMERO
NÚCLEO DE MEDICINA TROPICAL, UNIVERSIDADE DE BRASÍLIA, BRASÍLIA, DF, BRASIL.
•
Control Strategies
A SYSTEMATIC REVIEW OF PREVENTATIVE METHODS AGAINST HUMAN LEISHMANIASIS
INFECTION.
LISA STOCKDALE; ROBERT NEWTON
UNIVERSITY OF YORK, YORK, REINO UNIDO.
th
May 17 Friday
9:00 am – 9:30 am / Ariano Suassuna Auditorium
Science/public health gray zone in leishmaniasis: from science to policy
IVAN DARIO VELEZ; ALEJANDRA JIMENEZ; LILIANA LOPEZ; MARGARITA CORREA; SARA
MARIA ROBLEDO
PECET, UNIVERSITY OF ANTIOQUIA, MEDELLIN, COLÔMBIA.
•
Chair: C Pirmez / S Brandão Filho
Guilherme Werneck; John David; Jorge Alvar, DNDi
•
1.DIVISION OF EXPERIMENTAL THERAPEUTICS, WALTER REED ARMY INSTITUTE OF RESEARCH, SILVER
SPRING, MD, ESTADOS UNIDOS; 2.INSTITUT PASTEUR DE TUNIS, TUNIS, FRANÇA; 3.INSERM – UNIVERSITÉ
PIERRE ET MARIE CURIE (UMPC), PARIS, FRANÇA; 4.INSTITUTO CONMEMORATIVO GORGAS DE ESTUDIOS
DE LA SALUD, PANAMA CITY, PANAMA; 5.U.S. ARMY MEDICAL MATERIEL DEVELOPMENT ACTIVITY, FORT
DETRICK, ESTADOS UNIDOS.
9:00 am – 11:00 am / Room 1 – Amália Rodrigues
Tropical Treatment of CL
•
TOPICAL TREATMENT OF CUTANEOUS LEISHMANIASIS WITH ANFOLEISH, A 3%
AMPHOTERICIN B CREAM: REPORT OF CASES
PROGRAM UPDATE ON A TOPICAL PAROMOMYCIN PLUS GENTAMICIN FORMULATION
(WR279,396) FOR THE TREATMENT OF CUTANEOUS LEISHMANIASIS
MAX GROGL1; AFIF BEN SALAH2; PIERRE BUFFET3; NESTOR SOSA4; JEANNE A. NORWOOD5;
MARA KREISHMAN-DEITRICK5
•
PHASE 3 TRIAL OF TOPICAL PAROMOMYCIN WITH OR WITHOUT GENTAMICIN FOR
CUTANEOUS LEISHMANIASIS
Drugs for Neglected Diseases initiative, Latin America ■ Rua Santa Heloísa, Jardim Botânico, Rio de Janeiro, RJ, Brazil – CEP 22460-080
Tel: +55 (21) 2215 2941 ■ Email: [email protected] ■ Web: www.dndi.org.br
MARA KREISHMAN-DEITRICK1; AFIF BEN SALAH2; NATHALIE BEN MESSAOUD2; EVELYN
GUEDRI2; HECHMI LOUZIR2; MOURAD MOKNI2; ZAHER EL AHMADI3; GLORIA MORIZOT4;
PIERRE BUFFET5; PHILIP L SMITH1; KAREN M KOPYDLOWSKI1; JANET RANSOM; MAX GROGL6
1.US ARMY MEDICAL MATERIEL DEVELOPMENT ACTIVITY, FORT DETRICK, ESTADOS UNIDOS; 2.INSTITUT
VELEZ
PECET, UNIVERSIDAD DE ANTIOQUIA, MEDELLIN, COLÔMBIA.
•
PASTEUR DE TUNIS, TUNIS, TUNISIA; 3.REGIONAL DIRECTORATE OF HEALTH, SIDI BOUZID, TUNISIA;
4.INSTITUT PASTEUR, PARIS, FRANÇA; 5.INSERM - UNIVERSITE PIERRE ET MARIE CURIE (UMPC), PARIS,
FRANÇA; 6.WALTER REED ARMY INSTITUTE OF RESEARCH, SILVER SPRING, ESTADOS UNIDOS.
•
LOCAL TREATMENTS, THE BEST OPTION FOR CUTANEOUS LEISHMANIASIS
LILIANA LÓPEZ; SARA MARÍA ROBLEDO; ALEJANDRA JIMENEZ; CLAUDIA ASELA; IVAN D
DEVELOPMENT OF ANFOLEISH (3% AMPHOTERICIN B CREAM), A TOPICAL TREATMENT
FOR CUTANEOUS LEISHMANIASIS
SARA MARIA ROBLEDO1; CLAUDIA XIMENA ASELA1; ADRIANA MARIA RESTREPO1; ALBA
LUCIA CEBALLOS2; MARTHA BEATRIZ ROBLEDO1; JUAN JOSE ZULUAGA2; ALVARO GOMEZ2;
GWENAELLE CARN3; FABIANA ALVES3; FARROKH MODABBER3; IVAN DARIO VELEZ1
1.PECET, UNIVERSITY OF ANTIOQUIA, MEDELLIN, COLÔMBIA; 2.HUMAX PH, MEDELLIN, COLÔMBIA;
3.DNDI, GENEVA, SUÍÇA.
Posters:
•
Delphine Launay1; Denis Martin1; Stéphanie Braillard1; Preeti Vishwakarma2; Suman Gupta2;
2
3
4
4
4
Sunil Puri ; Vanessa Yardley ; Mvenkata Rao ; Vikram Ramanathan ; H Krishnappa ; Hari
Pati4; Andrew Thompson5
1
DRUGS FOR NEGLECTED DISEASES INITIATIVE, GENEVA - SWITZERLAND; 2CENTRAL DRUG RESEARCH
3
INSTITUTE, LUCKNOW - INDIA; LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE, LONDON - UK;
4
5
ADVINUS THERAPEUTICS, BANGALORE - INDIA; AUCKLAND CANCER SOCIETY RESEARCH CENTRE,
UNIVERSITY OF AUCKLAND, AUCKLAND – NEW ZEALAND
•
1
Poster #1377: Development of new drugs for Leishmaniasis: what can we learn from the in
vivo profiling of several promising chemical series
Stéphanie Braillard1; Eric Chatelain1; Charles E. Mowbray1; Delphine Launay1; Louis Maes2;
Andrew Thompson3
Conference website:
http://www.worldleish5.org/
DNDi website: www.dndi.org
DNDi Latin America website (Português, Español):
www.dndi.org.br
Media Contacts
Betina Moura
[email protected]
Mobile: +55 21 8122.2798
Mariana Abdalla
[email protected]
Mobile: +55 21 8108.2466
2
DRUGS FOR NEGLECTED DISEASES INITIATIVE, GENEVA - SWITZERLAND; LABORATORY OF
MICROBIOLOGY, PARASITOLOGY AND HYGIENE, UNIVERSITY OF ANTWERP, ANTWERP - BELGIUM;
3AUCKLAND CANCER SOCIETY RESEARCH CENTRE, UNIVERSITY OF AUCKLAND, AUCKLAND – NEW
ZEALAND
Poster #1190: DNDi-VL2098: a nitroimidazole derivative as a potential clinical candidate to
treat Visceral Leishmaniasis
•
Poster # 1389: Towards the identification of a back-up candidate for DNDi-VL2098 to treat
Visceral Leishmaniasis
Delphine Launay1; Eric Chatelain1; Stéphanie Braillard1; Preeti Vishwakarma2; Suman Gupta2;
Sunil Puri2; Vanessa Yardley3; Louis Maes4; Andrew Thompson5
1
DRUGS FOR NEGLECTED DISEASES INITIATIVE, GENEVA - SWITZERLAND; 2CENTRAL DRUG RESEARCH
INSTITUTE, LUCKNOW - INDIA; 3LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE, LONDON - UK;
4
LABORATORY OF MICROBIOLOGY, PARASITOLOGY AND HYGIENE, UNIVERSITY OF ANTWERP, ANTWERP BELGIUM; 5AUCKLAND CANCER SOCIETY RESEARCH CENTRE, UNIVERSITY OF AUCKLAND, AUCKLAND –
NEW ZEALAND
Follow us!
Facebook: facebook.com/dndi.org
Twitter: twitter.com/DNDi_HQ
YouTube: youtube.com/dndi2003
DNDi international
Drugs for Neglected Diseases initiative, Latin America ■ Rua Santa Heloísa, Jardim Botânico, Rio de Janeiro, RJ, Brazil – CEP 22460-080
Tel: +55 (21) 2215 2941 ■ Email: [email protected] ■ Web: www.dndi.org.br
DNDi Latin America
(Português/ Español)